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Summary: The Centers for Disease Control and Prevention (CDC) is working closely with the World 
Health Organization (WHO) and other partners to better understand the public health risk posed by 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a novel coronavirus that was first reported 
to cause human infection in September 2012. No cases have been reported in the United States. The 
purpose of this HAN Advisory is to provide updated guidance to state health departments and health care 
providers in the evaluation of patients for MERS-CoV infection including expansion of availability of 
laboratory testing and, in consultation with WHO, expansion of the travel history criteria for patients under 
investigation from within 10 to 14 days for investigation and modification of the case definition. Please 
disseminate this information to infectious diseases specialists, intensive care physicians, internists, 
infection preventionists, as well as to emergency departments and microbiology laboratories.
Background
MERS-CoV, formerly called “novel coronavirus,” is a beta coronavirus that was first described in 
September 2012, when it was reported to have caused fatal acute lower respiratory illness in a man in 
Saudi Arabia. Genetic sequence analyses have shown that this new virus is different from other known 
human coronaviruses, including the one that caused severe acute respiratory syndrome (SARS). 
Diagnosis relies on testing with real time reverse transcription polymerase chain reaction (RT-PCR) 
assays. There is no specific treatment for MERS-CoV infection; care is supportive.
As of June 7, 2013, 55 laboratory-confirmed cases of MERS-CoV infection have been reported to WHO—  
two from France, three from Italy, two from Jordan, two from Qatar, 40 from Saudi Arabia, two from 
Tunisia, one from the United Arab Emirates, and three from the United Kingdom (UK). Additional details 
can be found in the June 7, 2013 MMWR Early Release
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm62e0607a1 .htm?s cid=mm62e0607a1 w). To date, all 
cases have a direct or indirect link to one of four countries: Saudi Arabia, Qatar, Jordan, and the United 
Arab Emirates. No cases have been reported in the United States. Illness onsets were from April 2012 
through May 2013. Of the 55 cases, 31 were fatal, for a case-fatality rate of 56%. The median age of 
cases is 56 years. All of the patients were aged >24 years, except for two children, one aged 2 years and 
one aged 14 years.
Eight clusters of illnesses have been reported by six countries (France, Italy, Jordan, Saudi Arabia, 
Tunisia, and UK). These clusters provide clear evidence of human-to-human transmission of MERS-CoV. 
The largest cluster reported to date consists of 25 cases, 14 of which were fatal, associated with a health­
care facility in Al-Ahsa governorate in Saudi Arabia. Two of the case-patients in that cluster were health­
care personnel who acquired the infection after exposure to patients with confirmed MERS-CoV infection.
The first case reported by France was in a person with an underlying immunosuppressive condition who 
initially had abdominal pain and diarrhea and subsequently developed respiratory complications. This 
case raises the possibility that presentations may not initially include respiratory symptoms. Among 
cases reported to WHO in which more detailed information is available, most are reported to have chronic 
underlying medical conditions or immunosuppression; such persons may be at increased risk of MERS-
CoV infection or severe disease, or both. In some instances, sampling with nasopharyngeal swabs did 
not detect MERS-CoV by PCR; however, MERS-CoV was detected by PCR in lower respiratory tract 
specimens from those same patients. Therefore, lower tract respiratory specimens should be a priority for 
collection and PCR testing, in addition to nasopharyngeal swabs.
Recommendations
Recommendations and guidance on MERS-CoV case definitions, case investigation, specimen collection 
and shipment for testing, and infection control (including use of personal protective equipment) are 
available at the CDC MERS website (http://www.cdc.gov/coronavirus/MERS/index.html). Information and 
guidance posted on this website may change as we learn more about the virus. Please check CDC’s 
MERS website regularly for the most current information. State and local health departments with 
questions should contact the CDC Emergency Operations Center (770-488-7100 or eocreport@cdc.gov).
Surveillance
As a result of investigations suggesting incubation periods for MERS CoV may be longer than 10 days, 
the time period for considering MERS in persons who develop severe acute lower respiratory illness days 
after traveling from the Arabian Peninsula or neighboring countries* has been extended from within 10 
days to within 14 days of travel.
In particular, persons who meet the following criteria for “patient under investigation” (PUI) should be 
reported to state and local health departments and evaluated for MERS-CoV infection:
• A person with an acute respiratory infection, which may include fever (> 38°C , 100.4°F) and 
cough; AND
• Suspicion of pulmonary parenchymal disease (e.g., pneumonia or acute respiratory distress 
syndrome based on clinical or radiological evidence of consolidation); AND
• History of travel from the Arabian Peninsula or neighboring countries* within 14 days; AND
• Symptoms not already explained by any other infection or etiology, including clinically indicated 
tests for community-acquired pneumonia1 according to local management guidelines.
In addition, the following persons may be considered for evaluation for MERS-CoV infection:
• Persons who develop severe acute lower respiratory illness of known etiology within 14 days after 
traveling from the Arabian Peninsula or neighboring countries* but who do not respond to 
appropriate therapy; OR
• Persons who develop severe acute lower respiratory illness who are close contacts1 of a 
symptomatic traveler who developed fever and acute respiratory illness within 14 days of 
traveling from the Arabian Peninsula or neighboring countries.*
In addition, CDC recommends that clusters of severe acute respiratory illness (SARI) should be 
investigated and, if no obvious etiology is identified, local public health officials should be notified and 
testing for MERS-CoV conducted if indicated.
CDC requests that state and local health departments report PUIs for MERS-CoV and clusters of SARI 
with no identified etiology to CDC. To collect data on PUIs, please use CDC’s Interim Health Departments 
MERS-CoV Investigation Form_available at http://www.cdc.gov/coronavirus/mers/guidance.html. State 
health departments should FAX completed investigation forms to CDC at 770-488-7107 or attach in an 
email to eocreport@cdc.gov (subject line: MERS-CoV Patient Form).
Laboratory Testing
Testing of specimens for MERS-CoV is currently being conducted at CDC. The Food and Drug 
Administration (FDA) issued an Emergency Use Authorization (EUA) on June S, 2013, to authorize the 
use of the CDC Novel Coronavirus 2012 Real-time RT-PCR Assay (NCV-2-12 rRT-PCR Assay) to test for
MERS-CoV in clinical respiratory, blood and stool samples. This EUA is needed because, at this time, no 
FDA-approved tests that identify MERS-CoV in clinical specimens are available. This assay will be 
deployed to Laboratory Response Network (LRN) laboratories in all 50 states over the coming weeks. 
Updated information about laboratories with the capacity to conduct MERS testing with the NCV-2-12 
rRT-PCR Assay will be provided on CDC’s MERS website (http://www.cdc.gov/coronavirus/mers/case- 
def.html).
To increase the likelihood of detecting MERS-CoV, CDC recommends collection of specimens from 
different sites-- for example, a nasopharyngeal swab and a lower respiratory tract specimen such as 
sputum, bronchoalveolar lavage, bronchial wash, or tracheal aspirate. Specimens should be collected at 
different times after symptom onset, if possible. Lower respiratory tract specimens should be a priority for 
collection and PCR testing; stool specimens are of lower priority. Specimens should be collected with 
appropriate infection control precautions http://www.cdc.gov/coronavirus/mers/case-def.html.
Case Definitions
The MERS-CoV case definition continues to evolve and is available at
http://www.cdc.gov/coronavirus/mers/case-def.html. In consultation with WHO, the definition of a probable 
case of MERS has been updated to also include persons with severe acute respiratory infection with no 
known etiology with an epidemiologic link to a confirmed MERS-CoV case.
Infection Control
There is clear evidence of limited human-to-human transmission, possibly involving different modes, such 
as droplet and contact transmission, but further studies are required to better understand the risks. Until 
the transmission characteristics of MERS-CoV are better understood, patients under investigation and 
probable and confirmed cases should be managed in healthcare facilities using standard, contact, and 
airborne precautions. As information becomes available, these recommendations will be re-evaluated and 
updated as needed.
* Countries considered to be on or neighboring the Arabian Peninsula include Bahrain, Iraq, Iran, Israel, 
Jordan, Kuwait, Lebanon, Oman, Palestinian territories, Qatar, Saudi Arabia, Syria, the United Arab 
Emirates (UAE), and Yemen.
T Examples of respiratory pathogens causing community-acquired pneumonia include influenza A and B, 
respiratory syncytial virus, adenovirus, Streptococcus pneumoniae, and Legionella pneumophila.
1 Close contact is defined as 1) any person who provided care for the patient, including a health-care 
worker or family member, or who had other similarly close physical contact, or 2) any person who stayed 
at the same place (e.g., lived with or visited) as the patient while the patient was ill.
For more information:
For additional information, please consult the CDC MERS website at: 
http://www.cdc.g ov/coronavirus/mers/index.html
State and local health departments with questions should contact the CDC Emergency Operations Center 
(770-488-7100 or eocreport@cdc.gov).
The Centers for Disease Control and Prevention (CDC) protects people’s health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national, and international
organizations.
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